NEUROPAIN

Neuropathic pain: biomarkers and druggable targets within the endogenous analgesia system

 Coordinatore UNIVERSIDAD POMPEU FABRA 

 Organization address address: PLACA DE LA MERCE 10-12
city: BARCELONA
postcode: 8002

contact info
Titolo: Ms.
Nome: Eva
Cognome: Martin
Email: send email
Telefono: +34 935422140

 Nazionalità Coordinatore Spain [ES]
 Totale costo 8˙540˙389 €
 EC contributo 5˙992˙577 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-01-01   -   2018-12-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSIDAD POMPEU FABRA

 Organization address address: PLACA DE LA MERCE 10-12
city: BARCELONA
postcode: 8002

contact info
Titolo: Ms.
Nome: Eva
Cognome: Martin
Email: send email
Telefono: +34 935422140

ES (BARCELONA) coordinator 928˙000.00
2    ISLENSK ERFDAGREINING EHF

 Organization address address: Sturlugata 8
city: REYKJAVIK
postcode: 101

contact info
Titolo: Mr.
Nome: Frosti
Cognome: Jonsson
Email: send email
Telefono: +354 570 1900
Fax: +354 570 1903

IS (REYKJAVIK) participant 846˙937.00
3    CHARITE - UNIVERSITAETSMEDIZIN BERLIN

 Organization address address: Chariteplatz 1
city: BERLIN
postcode: 10117

contact info
Titolo: Ms.
Nome: Eveline
Cognome: Fräßdorf
Email: send email
Telefono: +49 30 450576024
Fax: 493084000000

DE (BERLIN) participant 653˙400.06
4    UNIVERSITY COLLEGE LONDON

 Organization address address: GOWER STREET
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Ms.
Nome: Gosia
Cognome: Kielbasa
Email: send email
Telefono: +44 20 3108 3064
Fax: +44 20 7813 2849

UK (LONDON) participant 545˙040.00
5    CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE

 Organization address address: Rue Laurent Fries 1
city: ILLKIRCH GRAFFENSTADEN
postcode: 67404

contact info
Titolo: Dr.
Nome: Steve
Cognome: Brooks
Email: send email
Telefono: +33 3 88 65 33 94
Fax: +33 3 88 65 32 03

FR (ILLKIRCH GRAFFENSTADEN) participant 500˙800.00
6    Nome Ente NON disponibile

 Organization address address: STENBACKINKATU 9
city: HELSINKI
postcode: 29

contact info
Titolo: Mr.
Nome: Alexander
Cognome: Andresen
Email: send email
Telefono: +358 9 471 72023
Fax: +358 9 471 75404

FI (HELSINKI) participant 500˙600.03
7    UNIVERSITAETSKLINIKUM BONN

 Organization address address: Sigmund-Freud-Strasse 25
city: BONN
postcode: 53105

contact info
Nome: Beate
Cognome: Becker
Email: send email
Telefono: +49 228 287 19454
Fax: +49 228 287 9019454

DE (BONN) participant 499˙800.00
8    INSTYTUT FARMAKOLOGII POLSKIEJ AKADEMII NAUK

 Organization address address: SMETNA 12
city: KRAKOW
postcode: 31-343

contact info
Titolo: Ms.
Nome: Lidia
Cognome: Radwan
Email: send email
Telefono: +48 12 6623238
Fax: 48126374500

PL (KRAKOW) participant 455˙000.00
9    GW PHARMA LIMITED

 Organization address address: Porton Down Science Park
city: SALISBURY
postcode: SP4 0QJ

contact info
Titolo: Dr.
Nome: Stephen
Cognome: Wright
Email: send email
Telefono: +44 1980557000
Fax: +44 1980557111

UK (SALISBURY) participant 454˙999.88
10    IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE

 Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
city: LONDON
postcode: SW7 2AZ

contact info
Titolo: Ms.
Nome: Tatjana
Cognome: Palalic
Email: send email
Telefono: +44 20 7594 6265

UK (LONDON) participant 402˙000.00
11    "Laboratorios del Dr Esteve, SA"

 Organization address city: Barcelona
postcode: 8041

contact info
Titolo: Dr.
Nome: José Miguel
Cognome: Vela
Email: send email
Telefono: 34934466244
Fax: +34 933473944

ES (Barcelona) participant 206˙000.03

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

analgesic    companies    emotional    biomarkers    treatment    behavioural    endogenous    private    pain    manifestations    models    neuropathic    identification    effectiveness    compounds    clinical    animal    paradigms   

 Obiettivo del progetto (Objective)

'Neuropathic pain has a high incidence in Europe and often affects the patient’s emotional balance and quality of life. Recent meta-analyses have shown that conventional analgesic drugs are not sufficiently effective in these patients and are limited by serious side effects. The search for new analgesics is extremely difficult despite identification of several new potential targets and enormous investment by the pharmaceutical industry. Important reasons for this failure are the poor predictive validity of currently available animal models of chronic pain, that do not simulate multidimensional clinical pain, and the high inter-individual variability of neuropathic pain manifestations and treatment responses. We will overcome these obstacles by an interdisciplinary collaboration between basic science groups, clinicians and leading private companies. This consortium will validate new animal models to evaluate the electrophysiological, behavioural, emotional and cognitive manifestations of neuropathic pain and the effectiveness of novel compounds. The use of these models in combination with other behavioural paradigms and new conditional knockout mouse lines for specific components of the endogenous opioid and cannabinoid system will permit the identification of novel druggable targets and biomarkers for neuropathic pain. Novel analgesic compounds acting on these endogenous systems developed by the private companies of the consortium will be tested in these new paradigms. Clinical studies will identify novel biomarkers for neuropathic pain using powerful genetics approaches and investigate treatment effectiveness with a translational focus based on cross validation of the findings in animals and humans.'

Altri progetti dello stesso programma (FP7-HEALTH)

OPCARE9 (2008)

A European Collaboration to optimise research for the care of cancer patients in the last days of life

Read More  

TRANSLINK (2013)

Defining the role of xeno-directed and autoimmune events in patients receiving animal-derived bioprosthetic heart valves

Read More  

TIRCON (2011)

Treat Iron-Related Childhood-Onset Neurodegeneration

Read More